P atients hospitalized with acute decompensated heart failure (ADHF) are at high risk for readmission, morbidity, and mortality. 1, 2 The increasing costs and frequency of admissions for ADHF are a focus of patient care efforts and healthcare reform, necessitating the identification of patients at high risk for future events to target therapeutic interventions. The most common symptoms accompanying admission for ADHF are dyspnea on minimal exertion or orthopnea, fatigue, and peripheral edema. 3 These symptoms reflect an acute or chronic increase in cardiac filling pressures, or congestion. Decongestion is therefore considered a primary goal of acute therapy. However, with current therapy, it is not Background-Congestion is the most frequent cause for hospitalization in acute decompensated heart failure. Although decongestion is a major goal of acute therapy, it is unclear how the clinical components of congestion (eg, peripheral edema, orthopnea) contribute to outcomes after discharge or how well decongestion is maintained.
clear (1) what proportion of patients are relieved of congestion during hospitalization, (2) what proportion remain free of congestion at short-term follow-up, and (3) which signs and symptoms of congestion best correlate with outcomes post discharge. The ADHF cohorts studied in the National Heart, Lung, and Blood Institute-sponsored Heart Failure Network trials of Diuretic Optimization Strategy Evaluation (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARRESS-HF) provide a unique opportunity to study these relationships given the specificity of entry criteria for baseline congestion and the consistent clinical assessment of congestion status at admission, before discharge and through 60 days. We hypothesized that clinical evidence of congestion would be relieved for the majority of patients hospitalized with ADHF and that most patients would remain free from congestion at 60-day follow-up. In addition, we hypothesized that residual congestion at hospital discharge would be associated with worse 60-day clinical outcomes.
Methods

Data Source and Study Population
This analysis used data from DOSE-AHF (ClinicalTrials.gov number, NCT00577135) and CARRESS-HF (ClinicalTrials.gov number NCT00608491). The design and results of both trials have been published previously. [3] [4] [5] [6] Briefly, both trials were prospective, double-blinded, and randomized patients hospitalized with ADHF at 9 regional heart failure (HF) centers to specific decongestion strategies. DOSE-AHF used a 2×2 factorial design to randomize 308 patients to low-dose versus high-dose furosemide therapy and continuous versus intermittent bolus administration of furosemide. CARRESS-HF randomized 188 patients with ADHF and worsened renal function, to stepped pharmacological therapy or ultrafiltration. Both trials included patients regardless of ejection fraction (EF) and required evidence of congestion before entry (detailed below). The same clinical assessment of congestion (jugular venous pressure [JVP] , orthopnea, and peripheral edema) was made and recorded in both trials at baseline, 24, 48, 72, 96, day 7 or discharge (whichever came first), and day 60 or early termination. All patients were followed up after discharge at regular intervals according to trial design and at 60 days for clinical assessments.
The DOSE-AHF and CARRESS-HF studies were approved by the Heart Failure Network Steering, Protocol Review and Data Safety Monitoring Committees, as well as each participating site's institutional review boards. All patients provided written informed consent.
Symptoms of Congestion
Clinical evidence of congestion (Table 1) was required for entry into both studies. Based on previous studies, 7-9 peripheral edema, elevated JVP, and orthopnea were included as markers of congestion. Each of these three characteristics was graded separately and then added together for the purpose of assessing their relationship to the combined outcome of death, hospitalization, or unscheduled emergency room or clinic visits through 60 days post randomization.
JVP did not correlate with subsequent outcomes in this analysis ( Figure I in the Data Supplement) and is not a part of patient symptom burden. Furthermore, the reliability of JVP assessment in general care settings has been called into question. 10 As inclusion of JVP did not provide added predictive value, it was not used in the present investigation. Rather, for this analysis, we combined the 2 resting symptoms of congestion that were systematically recorded: peripheral edema and orthopnea. Edema was categorized as trace/mild (0 points), moderate (1 point), or severe (2 points). Orthopnea was defined as present if the patient needed at least 2 pillows to breathe comfortably (2 points) or absent (0 points). The Orthodema Score was then generated by the sum of the individual orthopnea and edema scores ( Table 2) . A total score of 1 represents the presence of moderate edema without orthopnea. A score of 2 indicates the presence of orthopnea or severe peripheral edema, but not both. Scores of 1 to 2 represent low-grade congestion. High-grade congestion includes orthopnea and edema, with a score of 3 for orthopnea plus moderate edema, and a score of 4 if orthopnea is accompanied by severe edema.
As congestion was a prerequisite for study entry, patients with an orthodema score of 0 (similar to the overall analysis population) were excluded from the present study ( Figure 1 ). Orthodema scores were described at baseline, discharge, and at 60-day follow-up. If a hospitalization for heart failure occurred in the 60-day follow-up period, patients were assigned the worst orthodema score of 4. This occurred in 85 instances.
Outcomes
The primary clinical outcome analyzed was the time to the composite of death, rehospitalization, and unscheduled urgent clinic or emergency room visit by 60 days.
Statistical Analysis
Patients with an orthodema score of 1 to 2 were compared with patients with an orthodema score of 3 to 4 for baseline characteristics, presented as medians (25th, 75th percentiles) and compared with Wilcoxon rank-sum tests for continuous variables. Categorical variables were presented as percentages and compared with χ 2 tests. Baseline variables included clinical covariates of age, sex, systolic blood pressure, Characteristics of patients who demonstrated relief of congestion (orthodema score of 0) at discharge were compared with those with low-grade congestion (scores of 1-2) and those with high-grade congestion (scores of 3-4) and presented as medians (25th, 75th percentiles). Wilcoxon rank-sum tests were used for comparison of continuous variables and χ 2 tests were used for comparison of categorical variables.
Logistic regression models were used to analyze the association between orthodema scores at baseline or at discharge and the composite clinical outcome of death, rehospitalization, or unscheduled emergency room or clinic visit. Models were not adjusted for baseline characteristics as many contribute to congestion and doing so would diminish the practical utility of the orthodema score. No imputation or carry forward was used to account for missing data.
Weight changes in pounds were presented as mean values. A general linear model was used to compare the baseline congestion scores of 1 to 2 to 3 to 4 with respect to percentage weight loss at day 7 or discharge. Pairwise testing was performed to detect differences between the orthodema score groups. Length of stay was expressed in mean number of days.
A P value of 0.05 was considered statistically significant. SAS version 9.2 (Cary, NC) was used for all analyses.
Results
Congestion Status at Baseline
Of the 496 patients enrolled in the DOSE-AHF and CAR-RESS-HF trials from March 2008 to January 2012, 13 were excluded because of overlapping enrollment in both trials and an additional 20 were excluded because baseline values for edema or orthopnea were either missing or summed to an orthodema score of 0 ( Figure 1 ). High-grade orthodema (scores 3-4) was present in 65% of patients at enrollment. These subjects had lower use of angiotensin-convertingenzyme inhibitors or angiotensin receptor blockers, higher body mass index, worse renal function, and lower hemoglobin compared with those with low-grade orthodema (scores 1-2). No significant differences were observed for age, EF, etiology of HF, number of prior cardiovascular or HF hospitalizations, or prehospital furosemide dose (Table 3) .
Congestion Status at Discharge
Orthodema scores at all 3 time points (baseline, discharge, and 60-day follow-up) were available in 357 patients. After treatment with diuretic therapy and ultrafiltration, an orthodema score of 0 was achieved in 52% of patients at discharge; the remaining patients had scores of 1 to 2 (32%) or scores 3 to 4 (16%) as shown in Figure 2A . Compared with patients who achieved successful decongestion by discharge (orthodema score of 0), patients who remained congested at discharge (orthodema scores of 1-4) had higher body mass index (median of 34.1 versus 30.5; P<0.0001), were more likely to be diabetic (62% versus 51%; P=0.02), and had higher blood urea nitrogen levels (41 versus 37.5; P=0.03). None of these factors were significantly worse in patients with more congestion at baseline. No between-group differences were noted in age, sex, systolic blood pressure, heart rate, other comorbidity profile, EF, HF cause, or hemoglobin levels when comparing the patients with low-or high-grade orthodema with those without orthodema at discharge.
Weight Change
Weight recordings were available at baseline and discharge for 426 patients. Overall, no significant difference in weight change was observed for patients with baseline orthodema scores of 1 to 2 versus 3 to 4 (P=0.33). For patients who achieved decongestion (score 0), the average weight loss from baseline to discharge was 13.5 pounds. Patients with low-grade orthodema (scores 1-2) at baseline who attained decongestion at discharge lost a mean of 12.2 pounds, compared with a loss of 8.8 pounds in patients for whom low-grade orthodema persisted at discharge ( Table 4 ). The pattern of greater observed weight loss corresponding to decongestion was not consistent however. Comparable weight loss occurred even for patients with persistent orthodema at discharge. Of 282 patients with high-grade orthodema at baseline, 68 patients were discharged with persistent high-grade orthodema despite a weight loss of 14.2 pounds. Comparatively, the patients with high-grade orthodema at baseline who were successfully decongested and free of orthodema at discharge (n=123) lost a similar average of 14.6 pounds. After adjustment for baseline weight, the baseline orthodema score did not predict day 7/discharge absolute or relative weight loss.
Recongestion After Discharge
Of the 185 patients who were free from congestion at discharge, 35% remained free from congestion, 27% regressed to low-grade orthodema (scores of 1-2), and 38% regressed to high-grade orthodema (scores of 3-4), indicating recurrence of congestion at 60-day follow-up ( Figure 2B ). When compared with patients who maintained a decongested status, patients who experienced high-grade recongestion at 60 days were less likely to be on angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and aldosterone 
Congestion in Relation to Outcomes
Patients with more congestion at baseline (orthodema scores 3-4) had longer length of stay than patients with baseline orthodema scores 1 to 2 (mean, 8.9 versus 7.1 days) and at each time point after admission were more likely to still be in hospital (P=0.004). The presence of orthopnea at baseline or discharge was also associated with worse postdischarge outcomes. Orthopnea was present at baseline in 83% of patients, who had an event rate of 57% when compared with 30% in the patients without baseline orthopnea ( Figure II in the Data Supplement). Although baseline edema severity did not predict outcomes, persistent edema at discharge was associated with worse postdischarge outcomes ( Figure IIB in the in the Data Supplement). The 60-day rates of death, readmission, or unplanned clinic visit were 51%, 55%, and 71% in those with no edema, moderate, and severe edema, respectively, at discharge. As mentioned previously, there was no association between JVP and outcome either at baseline or at discharge ( Figure I in the Data Supplement). High-grade orthodema at discharge was associated with worse outcomes (Figure 3 ): patients with an orthodema score of 0 had an event rate of 50% as compared with 52% for patients with scores of 1 to 2 and 68% with scores of 3 to 4 (P=0.038).
Discussion
In the present analysis of patients undergoing therapy to relieve congestion, orthodema persisted in nearly half of subjects at hospital discharge. Even among patients achieving clinical decongestion, only one-third remained free from congestion at 60-day follow-up with the remaining two-thirds demonstrating relapse of orthopnea and edema. Although event rates were high regardless of discharge congestion status, the presence of orthodema was associated with even worse outcomes.
Identifying Congestion
There is increasing recognition of the contribution of clinical congestion not only to the symptomatic burden of patients but also to the national burden of rehospitalizations and to the progression of renal and liver dysfunction with cardiac cachexia. [11] [12] [13] [14] [15] [16] Multiple scores have been proposed to help identify and track congestion after HF admission.
JVP has been included in many of these scores, in part because of its recognized role in outpatient triage. The presence of jugular venous distention (JVD) in a stable ambulatory population was shown by Dries et al 7 to predict worse outcomes in the landmark Study of Left Ventricular Dysfunction (SOLVD) trial of angiotensin-converting enzyme inhibition. For hospitalized patients in the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) trial, Drazner et al 17 showed that HF physician estimates of JVP correlated with invasively measured right atrial pressure, which is a strong predictor of rehospitalization in studies including hemodynamic parameters. 18 In clinical practice, however, significant interobserver and intraobserver variability of clinician-assessed JVD have been noted. In the current analysis, the estimated level of elevation of JVP, whether measured at admission or discharge, was unrelated to subsequent outcome which may underscore the challenges associated with its use as either a criterion or an end point for effective therapy in AHF trials. In fact, specific JVP appraisal is no longer a core data element of the assessment in Heart Failure Network trials of ADHF.
Unlike JVD, orthopnea and edema are perceived by patients, for whom they often contribute substantially to their symptom burden. When consistently assessed, all 3 have been shown to reflect invasively measured filling pressures. Orthopnea correlates with high pulmonary capillary wedge pressures 7 and peripheral edema correlates with high right atrial pressures. 19 Orthopnea may be particularly important not only as a marker of high filling pressures but also as a contributor to sleep-disordered breathing, which has independently been associated with worse outcomes 20, 21 and shown to be decreased by reduction of filling pressures with intravenous vasodilation. 22 Of the signs and symptoms of congestion assessed in the outpatient setting at 1 month after discharge, orthopnea was the strongest single predictor of adverse outcomes, associated with a 62% rate of death or urgent transplant, compared with 23% in patients free of orthopnea at 1 month. 9 
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Weight Change and Decongestion
In the current analysis, weight loss did not consistently correlate with congestion status as measured by orthodema. Patients enrolled with high-grade orthodema at baseline that resolved completely by discharge lost an average of 14.6 pounds. Comparatively, of the patients with baseline high-grade orthodema, 24% were discharged with persistent high-grade orthodema, despite a similar weight loss of 14.2 pounds. These findings are consistent with the results of a previous analysis of the DOSE-AHF trial, which showed that increased weight loss at 72 hours was not associated with decongestion as assessed by dyspnea relief. 23 Weight change relative to an initial and optimized weight assessment may help determine how weight loss is associated with congestion relief during hospitalization for ADHF. This lack of correlation reflects marked interindividual variation in the amount of fluid retention that precipitates symptoms and the severity of symptoms that lead patients to seek hospitalization
Congestion Status at Discharge and Predicting Outcomes
A previous consensus document proposed an approach to grading congestion at the end of HF hospitalization by assigning point values to individual physical examination findings, patient symptoms, exercise testing, and laboratory values. 8 More recently, a congestion score from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) trial 24, 25 in patients with reduced EF was calculated by summing scores for orthopnea, JVD, and peripheral edema for maximum score of 9. By discharge, only 10% of patients had a score of ≥3 and experienced a HF rehospitalization rate of 35% versus 26% after a mean follow-up of 10 months. Only in the smallest subset of patients with the highest discharge congestion score was there an independent association between congestion status and worse clinical outcomes. In the present analysis, patients with evidence of orthodema at discharge had significantly higher morbidity and mortality compared with those without congestion, but the difference was modest. The 60-day adverse event rates were high irrespective of congestion status at discharge: 50% for patients free from orthodema, 52% for those with low-grade orthodema, and 68% with high-grade orthodema.
Recurrence of Congestion after Discharge
This study demonstrates the burden of recurrent congestion even after initial relief of congestion during acute hospitalization. Rates of recurrent congestion at 1 month were 51% and 27% for moderate and severe congestion, respectively, in the ESCAPE trial. 9 JVP, peripheral edema, and weight were also increased at 3 months in the ESCAPE trial, with slightly more recurrence in the arm that had been randomized to therapy guided by pulmonary artery catheters. 26 The rates of recurrent orthodema in the current study are comparable, with 27% and 35% of patients going on to develop low-and high-grade recurrent congestion by 2 months.
Focusing on the first month after discharge for HF patients with reduced EF, Lucas et al 9 developed a 0-to 5-point score based on the presence of orthopnea, edema, JVD >8 cmH 2 O, weight gain, and need to increase daily diuretic dose. They found that patients free of these markers at 1 month after discharge had a 2-year survival of 87%, compared with 67% in patients with 1 to 2 components of recurrent congestion, and 41% in patients with 3 to 5 components (P=0.00001). The most significant single predictor at 1 month was orthopnea.
This 5-point assessment of congestion at 1 month after discharge was validated by Rogers et al 27 in the more contemporary ESCAPE trial. Patients with no evidence of recurrent congestion at 1 month had a 9% risk of death and 31% risk of hospitalization at 6 months compared with patients with at least 3 components of recurrent congestion, who had 28% risk of death and 68% risk of rehospitalization. Furthermore, the 1-month congestion influenced quality of life and ambulation. Minnesota Living with Heart Failure questionnaire scores remained improved at 6 months after discharge in 50% of patients free of congestion at 1 month, compared with 37% of patients with at least 3 components of recurrent congestion. At 6 months, the 6-minute walk distance was 900 feet in 73% of patients free of congestion for the first month, when compared with 46% of patients with 1 to 2 components of congestion and only 26% of patients with 3 to 5 components of recurrent congestion at 1 month.
The 2 National Heart, Lung, and Blood Institutesponsored trials in this study, as well as the ESCAPE 28 study, were performed at centers with recognized expertise in care of acute HF and offered patients the benefit of additional surveillance through designated research staff, which has long been recognized to improve outcomes for patients in clinical trials whether receiving new or standard therapies. This is in addition to the established benefits of patient education and access to midlevel providers that are routine for patients cared for at the HF centers included in the National Heart, Lung, and Blood Institute Heart Failure Network. Recurrent congestion remains a fundamental challenge that we have not been able to address with our current approach to management of patients after hospital discharge. Until we can better understand and address this challenge of recongestion after hospital discharge, our ability to discern benefits of selected additional therapies during HF hospitalization may be limited. 
Limitations
This study is a post hoc retrospective analysis of 2 trials testing different therapies, but both required clinical evidence of congestion at enrollment and measured the impact of therapies to reduce circulating volume during hospitalization. The entry criteria and physical assessment forms were developed to collect data about the presence and changes in the components of congestion. Increasingly a focus of attention, the definition and quantification of congestion remain challenging and controversial. Any congestion score is somewhat arbitrary, and multiple thresholds and combinations could be constructed. In addition, individual clinical assessment of the presence and severity of JVD and edema is prone to variation, and patient assessment of orthopnea is not only variable between patients but possibly between time points for a given patient, who may be anxious to describe resolution of orthopnea perhaps to accelerate discharge.
Generalizability of assessments conducted in a clinical research setting requires validation in routine clinical practice. These trials were designed to achieve relief of congestion in rigorous clinical research environments that likely represent a level of vigilant attention above that feasible in routine practice. However, the components have been simplified to orthopnea and edema, which are classic clinical features universally recognized as descriptors of decompensated HF and typical targets for relief during hospitalization and noted during clinical evaluation.
Clinical Implications
The findings of the present analysis have distinct implications. First, it provides a simple symptom-based tool that may be used as a target for therapy in the hospital and outpatient setting. Second, it points out challenges in achieving decongestion despite rigorous clinical trial settings designed to evaluate decongestive therapies. Third, it highlights that even in those patients who are relieved of congestion, adverse event rates are high, underscoring the poor prognosis marked by hospitalization for AHF. Finally rates of recongestion are high in follow-up, suggesting a need to better understand the factors leading to recurrent congestion once patients return home.
Conclusions
Orthodema provides a clear target for therapy during hospitalization for ADHF and continuing care after discharge. Higher orthodema scores were associated with more postdischarge events, which support continued emphasis on decongestion during hospitalization. However, patients with relief of orthodema by discharge still experience high event rates after hospitalization for ADHF, in part, because of frequent recurrent congestion after discharge, which should be a major focus of efforts to prevent readmission with heart failure.
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